Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23039)	7/10/1998 10:18:00 AM
From: Phil Cressman	Read Replies (2) \| Respond to of 32384

Patents in the Drug business can be pretty broad, Would it be fair to say that Ligand has the potential to lock up extensive rights to the use of small molecule 'mimics'. I could be way off base but a broad patent could be worth a small fortune and force other Pharmas to strike deals with Ligand.

To: Henry Niman who wrote (23039)	7/10/1998 12:43:00 PM
From: Mudcat	Read Replies (3) \| Respond to of 32384

<SBH will develop the lead products, but LGND will file the patents and expand the technology to the new targets.> Henry, I am looking optimistically ahead and assuming the science will work on humans. Making that assumption, then for whom is this new science a blockbuster, SBH or Lgnd? I define blockbuster as product that will drive up a companies sales , earnings, and stock price. I'm not sure I understand your statement above. "SBH develops the lead products" I assume this means that its SBH's drug and they will get the majority of the profits from sales. "Lgnd will file the the patents" I assume this means that they will get a royalty from sales for letting SBH use their patent?